4-哌啶羧酸,1-(2,3-二氢-2-羰基-1H-咪唑并[4,5-b]喹啉-7-基)-,甲基酯 | 113259-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-哌啶羧酸,1-(2,3-二氢-2-羰基-1H-咪唑并[4,5-b]喹啉-7-基)-,甲基酯
• 英文名称: methyl 1-(2,3-dihydro-2-oxo-1H-imidazo<4,5-b>quinolin-7-yl)-4-piperidinecarboxylate
• 英文别名: methyl 1-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolin-7-yl)-4-piperidinecarboxylate；methyl 1-(2-oxo-1,3-dihydroimidazo[4,5-b]quinolin-7-yl)piperidine-4-carboxylate
• CAS: 113259-68-0
• 化学式: C₁₇H₁₈N₄O₃
• 分子量: 326.355
• InChiKey: QNTSROYOXYHHMS-UHFFFAOYSA-N

物化性质

• 沸点：
  443.0±45.0 °C(Predicted)
• 密度：
  1.335±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-哌啶羧酸,1-(2,3-二氢-2-羰基-1H-咪唑并[4,5-b]喹啉-7-基)-,甲基酯 在 盐酸 、 sodium hydroxide 作用下， 以 N-甲基乙酰胺 、 甲醇 为溶剂， 生成 1-(2,3-dihydro-2-oxo-1H-imidazo<4,5-b>quinolin-7-yl)-4-piperidinecarboxylic acid
  参考文献：
  名称：

  7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for

  摘要：

  2,3-二氢-2-氧基-1H-咪唑并[4,5-b]喹啉基胺衍生物的小说系列，化学式如下：其中R.sub.1是氢，较低的烷基；R.sub.2是氢，较低的烷基，较低的烷氧基，卤素；R.sub.3是氢，较低的烷基；R.sub.4是氢，较低的烷基，烷酰基，苯基烷酰基，其中苯基可以选择性地用卤素，较低的烷基，较低的烷氧基取代；R.sub.3和R.sub.4结合在一起形成吗啡啉基，哌啶基或吡咯啉基，可以选择性地用--CO.sub.2 R.sub.5或##STR2##取代，其中R.sub.5是氢或较低的烷基，R.sub.6是氢，较低的烷基，环烷基；4-R.sub.7-哌嗪基，其中R.sub.7是--CO.sub.2 R.sub.8，其中R.sub.8是较低的烷基，苯基，可以选择性地用最多2个卤素，较低的烷基或较低的烷氧基取代；含有7至10碳的苯基烷酰基，其中苯基未取代或独立地取代最多2个卤素，较低的烷基，较低的烷氧基。这些化合物是环磷酸腺苷磷酸二酯酶抑制剂，特别适用于抑制血小板聚集和/或作为心力补充剂。

  公开号：

  US04701459A1
• 作为产物：
  描述：

  1-(2,3-dihydro-2-oxo-1H-imidazo<4,5-b>quinolin-7-yl)-4-piperidinecarboxylic acid 生成 4-哌啶羧酸,1-(2,3-二氢-2-羰基-1H-咪唑并[4,5-b]喹啉-7-基)-,甲基酯
  参考文献：
  名称：

  MEANWELL, NICHOLAS A.;WRIGHT, JOHN J.

  摘要：

  DOI：

文献信息

• Aminoimidazoquinoline derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：EP0252503A1

  公开（公告）日：1988-01-13

  Novel series of 2,3-dihydro-2-oxo-1H-imidazo­[4,5-b]quinolinyl amine derivatives of Formula wherein R₁ is hydrogen, lower alkyl; R₂ is hydrogen, lower alkyl, lower alkoxy, halogen; R₃ is hydrogen, lower alkyl; R₄ is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R₃ and R₄ are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with -CO₂R₅ or -NR₅R₆ wherein R₅ is hydrogen or lower alkyl, and R₆ is hydrogen, lower alkyl, cycloalkyl; 4-R₇-piperazinyl wherein R₇ is -CO₂R₈ wherein R₈ is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.

  式中 2,3-二氢-2-氧代-1H-咪唑并[4,5-b]喹啉胺衍生物新系列 其中 R₁ 是氢、低级烷基；R₂ 是氢、低级烷基、低级烷氧基、卤素；R₃ 是氢、低级烷基；R₄ 是氢、低级烷基、烷酰基、苯基烷酰基，其中苯基可选择被卤素、低级烷基、低级烷氧基取代；R₃ 和 R₄ 连接在一起形成吗啉基、哌啶基或吡咯烷基，其中苯基可选择被 -CO₂R₅ 取代，或 -4-R₇-哌嗪基，其中 R₇ 是 -CO₂R₈ ，其中 R₈ 是低级烷基，苯基可选择被最多 2 个卤素、低级烷基或低级烷氧基取代；碳原子数为 7 至 10 的苯基烷酰基，其中苯基未被取代或独立地被最多 2 个卤素、低级烷基或低级烷氧基取代。这些化合物是环 AMP 磷酸二酯酶抑制剂，尤其可用作血小板聚集抑制剂和/或强心剂。
• Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility
  作者：Nicholas A. Meanwell、Ronald D. Dennis、Herbert R. Roth、Michael J. Rosenfeld、Edward Smith、J. J. Kim Wright、John O. Buchanan、Catherine L. Brassard、Marianne Gamberdella

  DOI：10.1021/jm00092a020

  日期：1992.7

  Two series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives incorporating an additional site for acid salt formation were synthesized and evaluated as inhibitors of human blood platelet cAMP phosphodiesterase (PDE) and ADP-induced platelet aggregation. The objective of this study was to identify compounds that blended potent biological activity with a satisfactory level of aqueous solubility. From a series of 7-aminoimidazo[4,5-b]quinolin-2-ones, biological and physical properties were optimally combined in the 1-piperidinyl derivative 11c. However, this compound offered no significant advantage over earlier studied compounds as an antithrombotic agent in an animal model of small vessel thrombosis. A series of 7-alkoxy alkanoic piperazinamide derivatives, in which the additional basic nitrogen atom was remote from the heterocyclic nucleus and accommodated in a secondary binding region of the cAMP PDE enzyme, demonstrated greater intrinsic cAMP PDE inhibitory activity. Structural modifications of this series focused on variation of the piperazine substituent and side-chain length. The lipophilicity of the N-substituent influenced biological potency and aqueous solubility, with substituents of seven carbon atoms or less generally providing acceptable solubility properties. The N-(cyclohexylmethyl)piperazinamide 21h was identified from this series of compounds as a potent inhibitor of platelet cAMP PDE, IC50 = 0.4 nM, and ADP-induced platelet aggregation, IC50 = 0.51-mu-M after a 3-min exposure and 0.1-mu-M after a 15-min exposure of platelet-rich plasma to the drug. Evaluation of 21h and representative analogues in vivo using a rabbit model of small vessel thrombosis revealed significantly greater antithrombotic efficacy compared to that of previously studied compounds with similar intrinsic biological activity measured in vitro but inferior aqueous solubility.
• US4701459A
  申请人：——

  公开号：US4701459A

  公开（公告）日：1987-10-20
• 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for
  申请人：Bristol-Myers Company

  公开号：US04701459A1

  公开（公告）日：1987-10-20

  Novel series of 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl amine derivatives of Formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl; R.sub.2 is hydrogen, lower alkyl, lower alkoxy, halogen; R.sub.3 is hydrogen, lower alkyl; R.sub.4 is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R.sub.3 and R.sub.4 are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with --CO.sub.2 R.sub.5 or ##STR2## wherein R.sub.5 is hydrogen or lower alkyl, and R.sub.6 is hydrogen, lower alkyl, cycloalkyl; 4-R.sub.7 -piperazinyl wherein R.sub.7 is --CO.sub.2 R.sub.8 wherein R.sub.8 is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.

  2,3-二氢-2-氧基-1H-咪唑并[4,5-b]喹啉基胺衍生物的小说系列，化学式如下：其中R.sub.1是氢，较低的烷基；R.sub.2是氢，较低的烷基，较低的烷氧基，卤素；R.sub.3是氢，较低的烷基；R.sub.4是氢，较低的烷基，烷酰基，苯基烷酰基，其中苯基可以选择性地用卤素，较低的烷基，较低的烷氧基取代；R.sub.3和R.sub.4结合在一起形成吗啡啉基，哌啶基或吡咯啉基，可以选择性地用--CO.sub.2 R.sub.5或##STR2##取代，其中R.sub.5是氢或较低的烷基，R.sub.6是氢，较低的烷基，环烷基；4-R.sub.7-哌嗪基，其中R.sub.7是--CO.sub.2 R.sub.8，其中R.sub.8是较低的烷基，苯基，可以选择性地用最多2个卤素，较低的烷基或较低的烷氧基取代；含有7至10碳的苯基烷酰基，其中苯基未取代或独立地取代最多2个卤素，较低的烷基，较低的烷氧基。这些化合物是环磷酸腺苷磷酸二酯酶抑制剂，特别适用于抑制血小板聚集和/或作为心力补充剂。
• MEANWELL, NICHOLAS A.;WRIGHT, JOHN J.
  作者：MEANWELL, NICHOLAS A.、WRIGHT, JOHN J.

  DOI：——

  日期：——